Human Vaccines, Paediatric & Adult Immunisation, Global Supply & Pandemic Preparedness
Vaccines
Executive Search
35+ Vaccines Placements — with an average 92 Days time-to-placement and a 12-month candidate guarantee.
35+
Vaccines Placements
92 Days
Avg. Time-to-Placement
88%
Offer Acceptance Rate
12 Months
Candidate Guarantee
Specialisation withinPharmaceuticals & Biotechnology·Innovating for Better Health
Vaccines is the immunisation-product tranche of pharma where India holds a globally-significant manufacturing-and-supply position — accounting for 60-65% of global vaccine volumes by dose through suppliers to UNICEF, Gavi, PAHO, and national immunisation programmes worldwide. The ecosystem spans listed and privately-held vaccine manufacturers (the world's largest vaccine manufacturer by volume headquartered in India, large privately-held Indian vaccine majors, listed integrated-vaccines-and-biologics operators, public-sector and state-owned vaccine-and-biological-products operators, India units of global vaccines MNCs, and the vaccines arms of large-cap listed Indian pharma majors), paediatric-vaccine specialists, adult-and-travel-vaccine specialists, emerging mRNA and viral-vector platform operators (India-headquartered mRNA-and-novel-platform biotech specialists), and pandemic-preparedness-and-emergency-use-authorisation operators. Leadership here requires fluency in multi-platform (recombinant, live-attenuated, inactivated, toxoid, conjugate, subunit, viral-vector, mRNA) vaccine-development-and-manufacturing, WHO-prequalification (WHO PQ) stewardship, national-immunisation-programme (UIP, Mission Indradhanush) supply-chain architecture, Gavi-and-UNICEF-tender stewardship, and the specific cold-chain-and-lyophilisation-and-fill-finish operating rhythm of vaccine manufacturing.
Is This Your Situation?
If any of these sound familiar, you're speaking to the right practice.
→Large India-based vaccine manufacturer running MD succession — confidential search with promoter-and-board alignment across multi-platform vaccine operating credibility, WHO-PQ-and-Gavi-tender stewardship, and the governance rhythm of a globally-significant vaccine operator.
→Emerging mRNA-platform vaccine operator hiring a Head of R&D with mRNA-and-LNP (Lipid Nanoparticle) platform credibility and multi-antigen development-and-clinical-trial stewardship.
→Vaccine manufacturer running Site Head succession for its flagship WHO-PQ-inspected multi-antigen site — leaders with BSL-2-and-BSL-3 containment and lyophilisation-and-fill-finish credibility.
→Vaccine operator hiring a Head of Global Supply to run Gavi-UNICEF-PAHO tender participation and multi-country-supply-commitments architecture.
Our Vaccines Track Record
Situation:
A listed pharma major expanding its vaccine-and-immunisation-products division needed Head of Vaccines succession. The brief required multi-platform (recombinant, conjugate, live-attenuated) development-and-commercialisation credibility, WHO-PQ-and-Gavi-tender stewardship, UIP-and-private-market portfolio architecture fluency, and the specific vaccine-commercial rhythm.
Outcome:
Placed a Head of Vaccines with prior head-of-vaccines tenure at an MNC vaccine operator and subsequent vaccine-business-head tenure at a large India-based vaccine manufacturer. The listed pharma major's vaccine-portfolio expansion and WHO-PQ submissions accelerated materially within 18 months of the Head's joining.
Situation:
An emerging India-based mRNA-platform vaccine scale-up building a multi-antigen pipeline needed Head of R&D succession. The brief required mRNA-and-LNP (Lipid Nanoparticle) platform credibility, multi-antigen development-and-clinical-trial stewardship, WHO-ICH-and-CDSCO regulatory architecture fluency, and the specific platform-scale-up R&D rhythm.
Outcome:
Placed a Head of R&D with prior head-of-vaccine-R&D tenure at a global biologics major and subsequent mRNA-platform leadership tenure at an emerging India-based vaccine scale-up. The operator's multi-antigen mRNA pipeline advanced across early-stage clinical milestones within 18 months of the Head's joining.
All client details anonymised. Specific mandates available for reference under NDA upon request.
Our Vaccines Practice
Vaccines is the immunisation-product tranche of pharma where India holds a globally-significant manufacturing-and-supply position — accounting for 60-65% of global vaccine volumes by dose through suppliers to UNICEF, Gavi, PAHO, and national immunisation programmes worldwide. The ecosystem spans listed and privately-held vaccine manufacturers (the world's largest vaccine manufacturer by volume headquartered in India, large privately-held Indian vaccine majors, listed integrated-vaccines-and-biologics operators, public-sector and state-owned vaccine-and-biological-products operators, India units of global vaccines MNCs, and the vaccines arms of large-cap listed Indian pharma majors), paediatric-vaccine specialists, adult-and-travel-vaccine specialists, emerging mRNA and viral-vector platform operators (India-headquartered mRNA-and-novel-platform biotech specialists), and pandemic-preparedness-and-emergency-use-authorisation operators. Leadership here requires fluency in multi-platform (recombinant, live-attenuated, inactivated, toxoid, conjugate, subunit, viral-vector, mRNA) vaccine-development-and-manufacturing, WHO-prequalification (WHO PQ) stewardship, national-immunisation-programme (UIP, Mission Indradhanush) supply-chain architecture, Gavi-and-UNICEF-tender stewardship, and the specific cold-chain-and-lyophilisation-and-fill-finish operating rhythm of vaccine manufacturing.
We place leaders across listed and privately-held vaccine manufacturers, paediatric-and-adult-vaccine specialists, MNC vaccine India units, emerging mRNA-and-viral-vector platform operators, and pandemic-preparedness operators. Engagements include CEO / MD searches for vaccine manufacturers, Head of Vaccines / Head of Immunisation-Products searches, Head of R&D / Head of Clinical Development placements, Head of Manufacturing / Site Head placements, Head of Quality / Head of Regulatory Affairs searches, and CFO placements with vaccine-sector credibility. Every mandate is retained and closed-network.
As a specialist CEO mandates in vaccine manufacturers, our practice also covers CTO and vaccine R&D leadership, our practice also covers Pharmaceuticals & Biotech practice overview, and as a source for Pharmaceuticals — biosimilars & biologics.
The Vaccines Landscape Today
India's vaccine sector supplies 60-65% of global vaccine volumes by dose — the world's largest vaccine manufacturer by volume (headquartered in India) alone manufactures ~1.5 billion doses annually across multiple antigen platforms. The world's largest vaccine manufacturer by volume (with a portfolio spanning COVID-19 vaccines, MMR, measles, rubella, oral polio, pentavalent DPT-HepB-Hib, rotavirus, and HPV), a large privately-held Indian vaccines major (with COVID-19, rotavirus, typhoid conjugate, cholera, and chikungunya vaccines), a listed integrated-vaccines-and-biologics operator (with COVID-19, pentavalent, TdaP, Japanese encephalitis, and typhoid conjugate vaccines), listed biologics-and-vaccines operators (including operators with DNA-plasmid vaccine firsts), privately-held vaccine-and-pharmaceuticals groups, public-sector and state-owned vaccine-and-biological-products operators, and India units of global vaccines MNCs (with HPV, zoster, rotavirus, influenza, meningococcal, pentavalent, and pneumococcal portfolios) are the principal vaccine operators. The Universal Immunisation Programme (UIP) under the Ministry of Health and Family Welfare covers 12 vaccines across paediatric and maternal immunisation. Mission Indradhanush and Intensified Mission Indradhanush target full immunisation-coverage expansion. Gavi (global vaccine alliance), UNICEF Supply Division, and PAHO (Pan American Health Organisation) tenders are the principal global procurement channels — Indian manufacturers collectively win the majority share of these tenders by volume. WHO Prequalification (WHO PQ) status is central for global-procurement eligibility. Emerging India-headquartered mRNA-platform operators (with the first India-developed mRNA vaccine for COVID-19) and viral-vector platforms represent the next-generation tranche. Pandemic-preparedness-and-emergency-use-authorisation (EUA) architecture, including CoWIN and similar digital-immunisation-registries, is now a permanent operating layer. Leadership in the sub-sector requires fluency in multi-platform vaccine-development-and-manufacturing, WHO PQ stewardship, UIP-and-Gavi-and-UNICEF supply-chain architecture, and cold-chain-and-lyophilisation-and-fill-finish operating rhythm.
Key Leadership Challenges in Vaccines
CEO / MD succession for listed and privately-held vaccine manufacturers — leaders with multi-platform vaccine operating credibility, WHO-PQ-and-Gavi-tender stewardship, UIP-and-national-immunisation-programme supply-chain discipline, and the governance rhythm of vaccine operators.
Head of Vaccines / Head of Immunisation-Products placements — multi-product pharma-and-biotech operators need Vaccine Heads with multi-platform development-and-commercialisation credibility.
Head of R&D / Head of Clinical Development (Vaccines) placements — vaccine operators need R&D Heads with multi-platform (recombinant, live-attenuated, inactivated, viral-vector, mRNA, conjugate) development credibility and WHO-ICH-and-CDSCO clinical-trial stewardship.
Head of Manufacturing / Site Head (Vaccines) placements — vaccine operators need Site Heads with BSL-2-and-BSL-3 containment credibility, cold-chain-and-lyophilisation-and-fill-finish operating discipline, and the specific multi-antigen-campaign-planning architecture.
Head of Quality / Head of Regulatory Affairs (Vaccines) placements — vaccine operators need QA-and-RA Heads with WHO-PQ-and-USFDA-and-EMA credibility, vaccine-lot-release stewardship, and the specific GMP-and-biosafety-and-data-integrity architecture of vaccine operations.
Head of Global Supply / Head of Gavi-and-UNICEF Tenders placements — vaccine operators need Supply-and-Tender Heads with multi-country-procurement-tender credibility and the specific Gavi-UNICEF-PAHO tender-economics architecture.
What We Look For in Vaccines Leaders
Across mandates, vaccines leadership tends to cluster into a small set of archetypes. We calibrate each search against the profile your board actually needs — not the one most commonly available.
The Vaccine MD / President
Executive who has run a vaccine manufacturer or multi-geography vaccine-and-biologics group — fluent in multi-platform vaccine operating credibility, WHO-PQ-and-Gavi-tender stewardship, UIP-and-national-immunisation-programme supply-chain discipline, and the governance rhythm of globally-significant vaccine operators.
The Head of Vaccines / Head of Immunisation-Products
Division leader with multi-platform development-and-commercialisation credibility, UIP-and-Gavi-and-private-market portfolio stewardship, and the specific vaccine-commercial-rhythm discipline. Often a career vaccine or biologics operator with subsequent Head of Vaccines leadership.
The Head of R&D / Clinical Development (Vaccines)
R&D leader with multi-platform (recombinant, live-attenuated, inactivated, viral-vector, mRNA, conjugate) development credibility, WHO-ICH-and-CDSCO clinical-trial stewardship, and the specific vaccine-development-economics architecture. Often a PhD or MD / PhD with subsequent industry R&D leadership.
The Vaccine Site Head / Head of Manufacturing
Operations leader with BSL-2-and-BSL-3 containment credibility, cold-chain-and-lyophilisation-and-fill-finish operating discipline, multi-antigen-campaign-planning architecture fluency, and the specific vaccine-GMP rhythm of WHO-PQ-inspected sites.
The Vaccine QA / RA Head
Compliance leader with WHO-PQ-and-USFDA-and-EMA credibility, vaccine-lot-release stewardship, GMP-and-biosafety-and-data-integrity architecture fluency, and the specific multi-regulatory-agency vaccine-inspection rhythm.
The Head of Global Supply / Tenders (Vaccines)
Commercial leader with multi-country-procurement-tender credibility, Gavi-UNICEF-PAHO tender-economics architecture fluency, multi-year-supply-commitments discipline, and the specific global-vaccine-procurement rhythm.
Regulatory & Compensation Context
Regulatory Backdrop
Vaccine operations sit at the intersection of CDSCO (Central Drugs Standard Control Organisation), WHO Prequalification (WHO PQ), USFDA (BLA — Biologics License Application), EMA, and NRA (National Regulatory Authority) frameworks globally. The Drugs and Cosmetics Act 1940 and the New Drugs and Clinical Trials Rules 2019 govern Indian vaccine approvals; CDSCO and the Subject Expert Committee (SEC) on vaccines oversee clinical-trial and marketing-authorisation decisions. WHO PQ status is central for Gavi-UNICEF-PAHO procurement eligibility — the WHO PQ programme assesses manufacturing-and-quality standards against WHO-GMP and programmatic suitability. ICH Q5A-Q5E (Quality of Biotechnological Products), Q6B (Specifications for Biotech Products), Q7 (GMP for APIs), and the WHO TRS (Technical Report Series) vaccine-specific guidelines provide the integrated quality architecture. BSL-2 and BSL-3 biosafety containment is mandated for specific antigen platforms (tuberculosis, typhoid, COVID-19 high-risk strains, and similar). The National Biosafety Committee (under DBT) and IBSC (Institutional Biosafety Committee) stewardship is required for GMO-based and viral-vector vaccines. Emergency Use Authorisation (EUA) architecture became a permanent operating layer during COVID-19. The Universal Immunisation Programme (UIP) and state-level-immunisation-programme tender architecture governs domestic public-procurement.
Compensation Architecture
Vaccine leadership compensation reflects the specialised-biologics-and-global-supply nature of the sub-sector. Listed-or-large-vaccine-manufacturer MD compensation can cross ₹10-25 crore fixed with multi-year promoter-equity-type architectures at privately-held operators; Head of Vaccines / Head of Immunisation-Products compensation ranges ₹5-12 crore; Head of R&D (Vaccines) for a multi-platform operator ranges ₹4-9 crore with platform-approval-and-WHO-PQ-linked variable; Site Head for a flagship WHO-PQ-inspected site ranges ₹3-6 crore. Emerging mRNA-and-platform-scale-ups frequently include founder-type equity architectures.
Roles We Typically Place
Why Gladwin International Leadership Advisors for Vaccines
CEO / MD searches for listed and privately-held vaccine manufacturers.
Head of Vaccines / Head of Immunisation-Products placements.
Head of R&D / Head of Clinical Development (Vaccines) placements.
Head of Manufacturing / Site Head (Vaccines) placements.
Head of Quality / Head of Regulatory Affairs (Vaccines) placements.
Head of Global Supply / Head of Gavi-and-UNICEF Tenders placements.
CFO placements with vaccine-sector credibility.
Organisations We Serve
The three largest India-based vaccine manufacturers (the world's largest vaccine manufacturer by volume, a large privately-held Indian vaccines major, and a listed integrated-vaccines-and-biologics operator)
Listed and privately-held Indian vaccine-and-biologics operators, public-sector vaccine-and-biological-products operators
India vaccines units of global vaccines MNCs
India vaccines units of global biologics-and-pharma MNCs
India-headquartered mRNA-and-viral-vector platform operators
Paediatric-vaccine and adult-and-travel-vaccine specialists
Pandemic-preparedness and emergency-use-authorisation operators
Vaccines leaders assessed on the Pharma & Biotech “HELIX” framework
Eight dimensions calibrated for pharmaceutical and biotechnology leadership. Dimensions are calibrated for vaccines mandates where relevant.
Parent Practice
Return to Pharmaceuticals & Biotechnology
Discuss a Vaccines Mandate
Confidential · No obligation
Response within 4 business hours · All enquiries handled by a senior practice partner · Strictly confidential